Navigation Links
First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development
Date:7/31/2014

NEW YORK and VIENNA, July 31, 2014 /PRNewswire/ --

AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising Parkinson's drug target, to enter clinical testing.

The Michael J. Fox Foundation for Parkinson's Research (MJFF) supported the study with a $ 1.5 million grant, and presented at the press conference on the impact a disease-modifying therapy would have for patients. The Foundation will support a follow-up study testing a boost vaccination, the next step toward a Phase II trial.

"A treatment that could slow or stop Parkinson's progression would be a game changer for the five million worldwide living with this disease and the many more who will become at risk as our population ages", said MJFF CEO Todd Sherer, PhD. "The AFF008 trial is one of the most promising efforts toward that goal, and we're proud to support this work of AFFiRiS AG."  

In this study, two different doses of PD01A were safe and well tolerated, meeting the primary endpoint of the trial. Secondary endpoints of the study included the induction of an alpha-synuclein-specific antibody response. A hallmark pathology of Parkinson's disease is aggregates of protein - chiefly alpha-synuclein - called Lewy bodies that accummulate in brain cells, leading to cell degeneration and cell death. Researchers hypothesize that reducing alpha-synuclein accumulation will be neuroprotective; AFFiRiS is using active immunotherapy to test that theory and develop a disease-modifying treatment.

PD01A was applied at two different doses (15 µg and 75 µg) to 12 patients per group. All received four vaccinations in monthly intervals, and all completed the study. Eight patients on best medical care, including standard symptomatic medication, served as a control group. Each patient was regularly seen and evaluated during a 12-month period.

Fifty percent of the vaccinated patients generated alpha-synuclein-specific antibodies as measured in serum samples. Additionally, vaccine-induced antibodies were detectable in cerebrospinal fluid. This induction of antibodies against alpha-synuclein is strong preliminary evidence in support of the principle of AFFiRiS' proprietary therapeutic vaccine.

Furthermore, analysis of clinical endpoints revealed a trend, consistent over all parameters, towards functional stabilization of the vaccinated groups as compared to non-vaccinated control patients. The pharmacodynamic profile of PD01A and its clinical effects will be the basis of later phase studies, should development continue.

"The safety and tolerability observed in this study, especially in a protein such as alpha-synuclein where we do not yet know its normal function, are encouraging," said Walter Schmidt, PhD, Co-founder and CEO of AFFiRiS AG. "We are grateful for the continued support of The Michael J. Fox Foundation as we progress in clinical development."

The next study will take place in Vienna, Austria and focus on assessing the immunological and clinical effects of a boost vaccination. Recruitment is expected to begin September.

A recording of the press conference will be made available at http://totalwebcasting.com/view/?id=affiris

Photographs from the press conference are available for download immediately after the event at http://imgur.com/a/EwZUK

Further pictures are available at http://www.affiris.com/html/de/presse_medien/bildmaterial_logos.php

Disclaimer:

This press release contains forward-looking statements and should not be used for investment decisions.

About AFFiRiS AG (By: May 2014) 

Based on its proprietary IP positions AFFiRiS develops tailor-made drugs mainly as Peptide-based vaccines. Target diseases include Alzheimer, Parkinson, Diabetes and other indications with attractive markets and unmet medical need. Alzheimer is the lead indication. Current investors are: MIG-Fonds and Athos Service GmbH, both Munich, Germany. AFFiRiS is located at the campus of the Vienna Biocenter, Vienna Austria and employs 95 highly qualified employees. http://www.affiris.com

About The Michael J. Fox Foundation for Parkinson's Research 

As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $ 450 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

http://www.michaeljfox.org

Contact AFFiRiS AG:
Mag. Julia Bock
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43/(0)1/798-15-75-303
E julia.bock@affiris.com
W http://www.affiris.com

Distribution:
PR&D - Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43/(0)1/505-70-44
E contact@prd.at
W http://www.prd.at


'/>"/>
SOURCE AFFiRiS AG
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Thoratec Schedules First Quarter Conference Call, Webcast
3. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
7. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
8. Insmed to Host 2012 First Quarter Earnings Conference Call
9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
10. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 The leader in accelerated orthodontics, ... is the recipient of the 2015 Townie Choice ... Class II medical device that speeds up orthodontic tooth ... pain often associated with treatment, AcceleDent was selected by ... annual Orthotown survey of the most reliable ...
(Date:2/9/2016)... The life of Dr. Jan Vilcek , celebrated immunologist ...  Twists of fate, combined with sheer grit, brought him from ... communist Czechoslovakia to New York City ... history by playing a key role in the development of ...  Dr. Vilcek brings readers along his improbable journey in his ...
(Date:2/9/2016)... The new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 ... that the North America continued to lead ... that translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... global anti-bacterial market is inclined towards North America ...
Breaking Medicine Technology:
(Date:2/10/2016)... Louis, Missouri (PRWEB) , ... February 10, 2016 ... ... 2016, in San Diego, will bring together more than 200 of the country’s ... healthcare for the future. , “The true benefit of the Forum is the ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Armune ... Apifiny® across their network of laboratory service centers across the country. Launched in ... aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests ...
(Date:2/10/2016)... Burnsville MN (PRWEB) , ... February 10, 2016 ... ... announced that it will attend the Ohio Safety Congress and Expo event March ... held at the Greater Columbus Convention Center. , As the longest running ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... – 1 UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional ... Elite Division - Time: 7:00pm – 10:00pm | Ticket Prices $30, Social ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Anxiety of ... since the start of Medicare Part D a decade ago, according to The ... from older adults on how they are coping with rapidly rising costs. “The ...
Breaking Medicine News(10 mins):